Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use

A matter of weeks away from the advisory committee review of the novel obesity drug lorcaserin, Arena's stock is flying high, yet the road to FDA approval, not to mention the daunting market, for obesity drugs looks more uncertain than ever